Glasgow-based Tilebio secures £1.6m to advance AI pathology models

Developing a proprietary language of cancer through artificial intelligence, Glasgow-based Tilebio Ltd has secured an estimated £1.6m in new funding. The company, which was incorporated on August 6, 2025, specializes in creating large-scale foundation models designed to interpret histopathology images.

Tilebio aims to automate the understanding of complex pathological data to enhance clinical diagnostics, biomarker discovery, and target development. Its technology processes images of tumour tissue using self-learning AI, allowing the software to understand cancer samples without the need for human labels. This method is intended to facilitate earlier and more accurate cancer detection for healthcare providers, pharmaceutical companies, and research institutions.

The funding round reached an estimated £1.6m, with the allotment date recorded as February 2, 2026, and the official filing made on May 6, 2026. This is a primary capital raise for the startup following its launch in late 2025.

Headquartered in Glasgow, the company currently employs seven people. Its work is rooted in research from institutions such as the University of Glasgow and Cancer Research UK. Tilebio operates within the biotechnology research sector, combining expertise in computer science, diagnostic histopathology, cancer surgery, and molecular medicine.

The company targets a global client base, offering its AI solutions to clinical laboratories and research organizations across North America, Europe, and Asia. By integrating large language models with deep learning, Tilebio seeks to automate image analysis to assist in clinical trial stratification and biomarker validation.